Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC811007 trace metal balance study in men with type 2 diabetes mellitus and healthy controls
ACTRN12612000293864Phase 2Completed
- Sponsor
- Protemix
- Start
- Jun 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of trientine in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Protemix. Primary endpoints: Change in 24-hour urinary copper excretion, Change in 2-hour urinary copper excretion and 1 more. Started Jun 2001; status: completed.
02
Drugs
trientine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12612000293864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000293864.